<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00471939</url>
  </required_header>
  <id_info>
    <org_study_id>CS I-020502/01</org_study_id>
    <nct_id>NCT00471939</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of I-020502 in Meshed Skin Autografting</brief_title>
  <official_title>A Phase II, Multi-Centre, Controlled Study of the Safety and Efficacy of Wound Healing Gel I-020502 (KUR-212) in Patients Undergoing Autologous Meshed Skin Grafting.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kuros Biosurgery AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter BioScience</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kuros Biosurgery AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, multi-centre, controlled study comparing the safety and tolerability on&#xD;
      wound healing following an application of I-020502 in a concentration of 1μg/mL TG-PDGF.AB&#xD;
      versus staples applied in the same patient to burn areas requiring autologous meshed skin&#xD;
      grafting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-related adverse events up to 28 days post surgery</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of AE/SAE, Changes in vital signs, Hematology/clinical chemistry, PDGF.AB/TG-PDGF.AB and antibodies, hypergranulation, Percentage and proportion of re-epithelialization/engraftment, Scar assessment, Time and resources for test site treatments</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Burns</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>I-020502</intervention_name>
    <description>1 mcg/mL TG-PDGF.AB</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent by the patient or his/her legal representative.&#xD;
&#xD;
          2. Male or female, aged ≥ 18 years.&#xD;
&#xD;
          3. Female with childbearing potential with a negative pregnancy test within 3 day prior&#xD;
             to surgery (screening).&#xD;
&#xD;
          4. Patients with burn wound(s) between ≥ 5 % and ≤ 50 % TBSA.&#xD;
&#xD;
          5. Patients with a contiguous deep partial thickness/full thickness wound(s) of two&#xD;
             comparable sites either contiguous or separate in the same location (e.g. leg) each&#xD;
             sized between 1% and 2% TBSA but not more than 400 cm2.&#xD;
&#xD;
          6. Patients who are willing to comply with treatment applications and instructions by the&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant or breast-feeding.&#xD;
&#xD;
          2. Patients with known or suspected allergies to any of the components of the wound&#xD;
             healing gel I-020502 (e.g. hypersensitivity to bovine proteins).&#xD;
&#xD;
          3. Digits, head, genitalia, palms of hands, soles of feet, and face are excluded as test&#xD;
             sites.&#xD;
&#xD;
          4. Electrical and/or chemical burns.&#xD;
&#xD;
          5. Patients that are judged to have significant pulmonary compromise.&#xD;
&#xD;
          6. Transcutaneous tissue oxygenation &lt; 90%.&#xD;
&#xD;
          7. Clinically significant infections at wound sites.&#xD;
&#xD;
          8. Clinically significant systemic infections.&#xD;
&#xD;
          9. Suspicion or presence of active systemic or local cancer or tumor of any kind.&#xD;
&#xD;
         10. Patients with known immunodeficiency disorders, either congenital or acquired.&#xD;
&#xD;
         11. Patients with vascular or skin disorders that directly affect the designated wound&#xD;
             site.&#xD;
&#xD;
         12. Patients with Diabetes mellitus.&#xD;
&#xD;
         13. Patients with chronic malnourishment.&#xD;
&#xD;
         14. Chronic treatment with immunosuppressive drugs or systemic corticosteroids within the&#xD;
             last 2 months prior to surgery.&#xD;
&#xD;
         15. Any other acute or chronic concurrent medical conditions that in the Investigator's&#xD;
             opinion are a contraindication to skin mesh grafting and study participation.&#xD;
&#xD;
         16. Participation in another investigational study within 30 days prior to surgery, for&#xD;
             investigational devices, or within the last three months for investigational drugs&#xD;
             related to wound healing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus Lehnhardt, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinik für Plastische Chirurgie und Schwerbrandverletzte</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinik für Plastische Chirurgie und Schwerbrandverletzte</name>
      <address>
        <city>Bochum</city>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>May 9, 2007</study_first_submitted>
  <study_first_submitted_qc>May 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2007</study_first_posted>
  <last_update_submitted>March 2, 2009</last_update_submitted>
  <last_update_submitted_qc>March 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Virginia Jamieson</name_title>
    <organization>Kuros Biosurgery AG</organization>
  </responsible_party>
  <keyword>Burn, Meshed skin graft, PDGF</keyword>
  <keyword>deep partial thickness or full thickness burns</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

